Cancer from hpv

Searched over 200M research papers

Research Analysis by Consensus

Beta · 20 papers

Consensus Meter

Yes

Possibly

Understanding Cancer from HPV: A Comprehensive Overview

HPV and Cancer: An Overview

Human Papillomavirus (HPV) and Its Role in Cancer

Human papillomavirus (HPV) is a significant cause of various cancers, particularly in the anogenital region and the oropharynx. Nearly all cervical cancers are attributable to HPV, with the virus also responsible for a substantial fraction of other anogenital cancers (vagina, vulva, penis, anus) and oropharyngeal cancers . HPV types 16 and 18 are particularly notorious, accounting for about 70% of cervical, vaginal, and anal cancers, and a significant portion of vulvar, penile, and oropharyngeal cancers.

Epidemiology and Global Burden

Global Incidence and Distribution

HPV is responsible for approximately 4.5% of all cancers worldwide, translating to around 630,000 new cancer cases annually. The burden is significantly higher in women (8.6%) compared to men (0.8%). Cervical cancer alone accounts for 83% of HPV-attributable cancers, with the majority occurring in less developed countries. Other notable HPV-related cancers include those of the vulva, vagina, anus, penis, and oropharynx .

Biological Mechanisms and Pathogenesis

HPV Oncoproteins and Carcinogenesis

HPV's oncogenic potential is primarily driven by its viral oncoproteins, E6 and E7, which interfere with critical cellular processes. E6 leads to the degradation of p53, while E7 targets pRb, facilitating uncontrolled cell division and contributing to carcinogenesis. These oncoproteins also alter DNA repair mechanisms, angiogenesis, and apoptosis, further promoting cancer development.

Post-Infection Microenvironment

HPV-infected cells create a supportive post-infection microenvironment (PIM) that aids in viral persistence and malignant progression. This environment involves a complex interplay between virus-infected cells, immune cells, and host stroma, along with various chemokines, cytokines, extracellular vesicles, and metabolites . Chronic inflammation and immune evasion are key features of this microenvironment, facilitating the progression to cancer.

Prevention and Vaccination

HPV Vaccination

Vaccination against HPV is a critical strategy in preventing HPV-related cancers. The 9-valent HPV vaccine (9vHPV) targets multiple oncogenic HPV types, including 16, 18, 31, 33, 45, 52, and 58, as well as non-oncogenic types 6 and 11 that cause genital warts. Universal access to vaccination, especially in less developed countries, is essential to reduce the global burden of HPV-attributable cancers .

Current Screening and Treatment

Screening and Clinical Trials

While screening and prevention of cervical cancer have significantly improved, other anogenital cancers remain challenging to confirm. Current clinical trials focus on improving testing for all HPV-associated cancers and enhancing treatment options. Immunotherapy is emerging as a promising approach, with early-phase studies exploring antigen-specific treatments showing modest but hopeful results.

Conclusion

HPV is a major contributor to various cancers, with cervical cancer being the most prominent. Understanding the biological mechanisms, global burden, and preventive strategies is crucial in combating HPV-related cancers. Vaccination remains a cornerstone of prevention, while ongoing research and clinical trials aim to improve screening and treatment, offering hope for better management and outcomes in HPV-associated malignancies.